CRISPR

CRISPR for Androgenetic Alopecia: The First Human Safety Data Has Arrived

A Phase 1 trial testing CRISPR-Cas9 to edit the androgen receptor gene in scalp follicles has reported its first safety data. No serious adverse events, and one unexpected finding worth paying attention to.